ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (AMEX:ISV) -- an ophthalmic therapeutics, diagnostics and drug delivery company, today announced that it has entered into a worldwide, exclusive royalty bearing licensing agreement with Pfizer Inc. (NYSE:PFE) under Pfizer’s Patent family titled “Method of Treating Eye Infections with Azithromycin”. Pfizer’s granting of this license will enhance the position and marketability of InSite’s AzaSite franchise.
